Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

about

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

Item

http://www.wikidata.org/entity/Q46063736

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

@en

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

@nl

type

Item

label

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

@en

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

@nl

prefLabel

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

@en

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

@nl

P1476

Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

@en

P2093

Carl E Allen

http://www.w3.org/2001/XMLSchema#string

Catherine E Terrell

http://www.w3.org/2001/XMLSchema#string

David A Hildeman

http://www.w3.org/2001/XMLSchema#string

Eileen E Elfers

http://www.w3.org/2001/XMLSchema#string

Jay N Greenberg

http://www.w3.org/2001/XMLSchema#string

Jonathan P McNally

http://www.w3.org/2001/XMLSchema#string

Julie Kanter

http://www.w3.org/2001/XMLSchema#string

Kaitlin R Carroll

http://www.w3.org/2001/XMLSchema#string

Michael B Jordan

http://www.w3.org/2001/XMLSchema#string

Michael Joyce

http://www.w3.org/2001/XMLSchema#string

P2860

THE EVOLUTION OF ADAPTIVE IMMUNITY

Diseases associated with defective responses to DNA damage

Targeting DNA damage response in cancer therapy

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139

Modes of p53 regulation

The cell cycle time of CD8+ T cells responding in vivo is controlled by the type of antigenic stimulus.

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.

Kinetics of p53 binding to promoter sites in vivo.

Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses

P304

E4782-E4791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1703683114

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Scott Millen

Jonathan D. Katz

P577

2017-05-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28533414

http://www.w3.org/2001/XMLSchema#string

P932

5474825

http://www.w3.org/2001/XMLSchema#string